These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 38178238)

  • 1. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
    Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization.
    Petrilla A; Marrett E; Shen X; Kwong WJ; Pezalla E
    Am Health Drug Benefits; 2020 Feb; 13(1):21-31. PubMed ID: 32165996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
    BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis.
    Yarborough BJ; Stumbo SP; Janoff SL; Yarborough MT; McCarty D; Chilcoat HD; Coplan PM; Green CA
    Drug Alcohol Depend; 2016 Oct; 167():49-56. PubMed ID: 27520885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
    J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths.
    Karami S; Ajao A; Wong J; Zhang D; Meyer T; Ding Y; Secora A; Major JM; Gill R; Chai GP; Zhao Y; McAninch J
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):735-751. PubMed ID: 36779261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone.
    Weiner SG; Hendricks MA; El Ibrahimi S; Ritter GA; Hallvik SE; Hildebran C; Weiss RD; Boyer EW; Flores DP; Nelson LS; Kreiner PW; Fischer MA
    PLoS One; 2022; 17(4):e0266561. PubMed ID: 35381052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
    Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
    Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study.
    Black JC; Margolin ZR; Olson RA; Dart RC
    JMIR Public Health Surveill; 2020 Jun; 6(2):e17073. PubMed ID: 32597786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
    Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A
    Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.